LIOTONTRAUM GEL 40G 2%+5%

LIOTONTRAUM 2% + 5% GEL

active ingredients

100 g gel contains: Extract 2 g Salicylate 5 g Excipients with known effects: propylene glycol and butylhydroxytoluene. For the full list of excipients, see paragraph 6.1.

Excellent

Lavender essence, nerolene essence, carboxypolymethylene, meglumine, propylene glycol, ethyl alcohol, sodium edetate, exyldecanol and laurate exyldecyldecyl, hetoxyglycol, butylhydroxytoluol, titanium dioxide, purified water.

Therapeutic indications

Minor trauma.

Contraindications

Hypersensitivity to active ingredients or any of the excipients listed in paragraph 6.1. Apply only on the intact skin. LIOTONTRAUMA gel should not be used on open injuries (low), mucosa and skin areas treated with radiation. Do not apply simultaneously in the same area as other skin medications. Use in children under the age of 12 is contraindicated. Do not use for prolonged periods without the advice of a doctor.

Population

Apply and spread a thin layer of LIOTONTRAUMA gel on the skin of the area to be treated from 1 to 3 times a day.

Conservation

Do not store at temperature above 30 ° C.

Warnings

As a preparation for topical applications, its use must be exclusively external. Prolonged use of topical products can give rise to awareness-raising phenomena. Avoid contact with eyes. Important information about some excipients LIOTONTRAUMA gel contains propylene glycol that can cause skin irritation. LIOTONTRAUMA gel contains butylhydroxytoluol (or butylhydroxytoluene) which can cause local skin reactions (e.g. contact dermatitis), or irritations of the eyes and mucosa.

Interactions

No interactions with other medicines have been reported.

Effects

Immune system disorders: in rare cases hypersensitivity reactions such as redness, dequamation and dehydration of the skin may appear. Pathologies of skin and subcutaneous tissue: contact dermatitis. Reporting of suspicious adverse reactions The reporting of suspicious adverse reactions that occur after the authorization of the medicinal product is important, as it allows continuous monitoring of the benefit/risk ratio of the medicinal product. Healthcare workers are required to report any suspected adverse reaction via the national reporting system at: www.agenziafarmaco.gov.it/content/come-segnalare-una-sospetta-reazione-avversa.

Overdosing

No overdose cases have been reported.

Pregnancy

There is no data on the use of LIOTONTRAUMA in pregnant women. The use of LIOTONTRAUMA is not recommended during pregnancy if not under strict medical control. However, prolonged use (maximum 3 weeks) of the product should be avoided on extended skin areas during pregnancy.

Food

Avoid using the gel on the breast during breastfeeding.

Source: Farmadati